68Ga-PFA2 PET scan to detect Annexin A2‑positive tumors
PET Imaging Study of 68Ga-PFA2 Probe for Annexin A2-Positive Tumors
This will try a new 68Ga‑PFA2 PET scan to see if it can detect Annexin A2‑positive tumors in adults with breast, lung, or pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07331532 on ClinicalTrials.gov |
What this trial studies
This is a single‑site observational imaging project using a novel radiotracer, 68Ga‑PFA2, that binds Annexin A2 to highlight tumor invasion and metastasis. Enrolled participants will undergo 68Ga‑PFA2 PET/CT imaging and results will be compared with standard imaging, pathology from planned biopsies or surgeries, and clinical follow‑up. The goal is to characterize tracer uptake patterns in Annexin A2‑positive tumors and determine whether the imaging provides additional information about metastatic spread beyond current methods. No investigational treatment is given; the protocol focuses on image acquisition and correlation with existing diagnostic data.
Who should consider this trial
Good fit: Enrollment is limited to adults aged 18–80 with confirmed lung cancer who are scheduled for pathological biopsy or surgical treatment within the next two months and who can give informed consent.
Not a fit: Patients who have contraindications to PET/CT or to 68Ga‑PFA2 administration, those with other active malignancies or severe comorbidities, cognitive impairment preventing consent, or who fall outside the 18–80 age range are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the scan could allow earlier or more accurate detection of invasive or metastatic disease and help doctors tailor treatment plans.
How similar studies have performed: Targeted PET tracers for other tumor markers (for example PSMA or HER2 tracers) have shown clinical value, but Annexin A2‑targeted imaging is relatively novel with limited published human data so far.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18-80 years. * Diagnosed with confirmed lung cancer. * Scheduled to undergo pathological tissue biopsy or surgical treatment within the next two months. * Able to fully comprehend and voluntarily participate in the study. * Able to provide informed consent. * Capable of cooperating independently to complete the examinations. Exclusion Criteria: * Patients with other malignancies or severe comorbidities that affect their ability to participate. * Patients unable to provide informed consent due to cognitive impairment. * Patients with contraindications to PET/CT scans or 68Ga-PFA2 administration.
Where this trial is running
Beijing, Beijing Municipality
- Peking university first hospital nuclear medicine — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Tingting Yuan
- Email: biluohtt@163.com
- Phone: +86-13051707479
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.